Palforzia Shortage Update: What Patients Need to Know in 2026

If your child has been on Palforzia — or if you were hoping to start this peanut allergy treatment — the news coming out of 2026 is significant. Palforzia is being voluntarily discontinued by its manufacturer, and the countdown clock is now ticking. Here is the complete patient update on what is happening and what you need to do.

The Bottom Line: Palforzia Is Being Discontinued

In January 2026, Stallergenes Greer — the pharmaceutical company that acquired Palforzia in 2023 — announced that it would voluntarily cease commercialization of Palforzia effective July 31, 2026. This is not an FDA recall. It is not a safety issue. The drug works. The company made a business decision that the complex clinical requirements and administrative burdens of the REMS (Risk Evaluation and Mitigation Strategy) program limited market adoption enough that the product was no longer commercially viable.

For the approximately 1 million children in the U.S. with peanut allergy, and particularly the thousands who were on Palforzia therapy, this announcement has caused significant concern and confusion. Here is what the timeline looks like and what it means for patients.

Full Palforzia Discontinuation Timeline

January 2026: Stallergenes Greer publicly announced the voluntary discontinuation decision. Patients and providers notified.

February 2026: Final expansion to toddler age range (1-3) had just been launched in the U.S. in early 2025, meaning toddlers who recently started therapy are also affected.

March-April 2026: Healthcare providers advised not to start new patients. Initial Dose Escalation packs became restricted or unavailable. Patients mid-treatment urged to contact allergist and Palforzia Pathway Hub.

July 31, 2026: Full commercialization ends. No new production. Remaining inventory distributed to patients already in therapy, but supply will not be replenished.

What Is the Current Supply Situation?

As of mid-2026, Palforzia supply is increasingly constrained. Remaining inventory exists at some specialty pharmacies and REMS-certified dispensing locations, but availability varies significantly by geography and dose level. Up-dosing packs — including the 3 mg level — and the 300 mg maintenance sachets are the dose forms patients are most urgently seeking.

Initial Dose Escalation packs became unavailable or restricted first, meaning new patients can no longer start Palforzia therapy. Patients already in the Up-Dosing or Maintenance phases are the priority for remaining inventory.

Why Did This Happen? A Brief History of Palforzia

Palforzia was originally developed by Aimmune Therapeutics and received historic FDA approval in January 2020 for children ages 4-17. Early projections estimated it would reach $1.28 billion in annual sales by 2024. Instead, market performance fell far short of expectations, driven by:

The COVID-19 pandemic disrupting the critical first years of commercialization

Heavy administrative burden from the REMS program limiting the number of REMS-certified clinics

Competition from office-based peanut OIT at significantly lower cost

Insurance access challenges requiring prior authorization with inconsistent approval rates

Nestlé Health Science acquired Aimmune in 2020 and subsequently sold Palforzia to Stallergenes Greer in September 2023. Following a strategic review, Stallergenes Greer made the discontinuation decision in January 2026.

39,049+ patients found their medications in stock

39K+

Find Palforzia 3 mg In Stock Today →

What Should Patients Do Right Now?

Call your allergist immediately. Discuss your child's current dose level, how much supply you have, and what a transition plan looks like.

Contact the Palforzia Pathway Patient Hub. Call 1-844-PALFORZ (1-844-725-3679) to ask about remaining supply and transition support.

Do not stop Palforzia abruptly. Work with your allergist on a planned transition — stopping suddenly can reverse desensitization.

Ask about office-based OIT. Your allergist may be able to continue your child's desensitization using peanut flour at the dose level already reached.

Ask about Xolair (omalizumab). FDA-approved for food allergy since February 2024, Xolair may be an appropriate option for some patients.

How medfinder Can Help

While supply lasts, medfinder can help you find which specialty pharmacies near you still carry Palforzia at your child's dose level. medfinder calls pharmacies on your behalf and texts you the results — saving you the time and frustration of making dozens of calls yourself. Given the urgency of the supply situation, every day matters.

Skip the calls, skip the stress.

Find Palforzia 3 mg In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Is the Peanut Allergy Treatment Field Going Away?

No. Palforzia's exit is a setback, but the treatment landscape continues to advance. Office-based OIT is expanding, Xolair is FDA-approved for food allergy, and several new treatments are in clinical trials. Palforzia leaves behind a legacy of clinical research and proof that food allergen desensitization is possible. The journey continues. For a full breakdown of what's available now, read our guide on alternatives to Palforzia.